Zobrazeno 1 - 10
of 311
pro vyhledávání: '"epidermal growth factor receptor inhibitor"'
Publikováno v:
Zhongguo quanke yixue, Vol 26, Iss 36, Pp 4527-4534 (2023)
Background Targeted therapy, represented by epidermal growth factor receptor-targeting tyrosine kinase inhibitors (EGFR-TKIs) , has significantly prolonged the survival time of patients with EGFR mutations with relatively mild adverse reactions, and
Externí odkaz:
https://doaj.org/article/9e06302af05e4eb2a17758a4f8497f2e
Autor:
Christopher Iriarte, MD, Jonathan H. Young, MD, PhD, Michael S. Rabin, MD, Nicole R. LeBoeuf, MD, MPH
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100415- (2022)
A 45-year-old woman with a history of lung adenocarcinoma treated with osimertinib developed purpuric plaques and vesicles on the lower extremities after 5 months of therapy. Skin biopsy revealed leukocytoclastic vasculitis (LCV). A workup for system
Externí odkaz:
https://doaj.org/article/32d523b9ad9f451da4e1b1353f6e6723
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Acta Pharmaceutica, Vol 71, Iss 3, Pp 415-428 (2021)
1-(4-(Pyrrolidin-1-yl-methyl)phenyl)-3-(4-((3-(trifluoromethyl) phenyl)amino)quinazolin-6-yl)urea (ZCJ14), a novel epidermal growth factor receptor (EGFR) inhibitor, with diarylurea moiety, displays anticancer effect. In the present study, an LCMS/MS
Externí odkaz:
https://doaj.org/article/2e95e5206504479781f5ebd219d9c593
Autor:
Pattamon Lertpichitkul, MD, Jade Wititsuwannakul, MD, Pravit Asawanonda, MD, DSc, Pawinee Rerknimitr, MD, MSc
Publikováno v:
JAAD Case Reports, Vol 6, Iss 2, Pp 86-88 (2020)
Externí odkaz:
https://doaj.org/article/c2fd7071a08b4b9da2ff311cb6c5240c
Publikováno v:
Clinical Case Reports, Vol 9, Iss 5, Pp n/a-n/a (2021)
Abstract Cetuximab can be used for the treatment of advanced basal cell carcinoma, especially when the patient cannot tolerate routine chemotherapy. Future studies are needed to confirm it.
Externí odkaz:
https://doaj.org/article/c28015ba0e5f47adb8a7f7a528eccba8
Autor:
Raffaele Parrozzani, Giuseppe Lombardi, Edoardo Midena, Davide Londei, Marta Padovan, Giulia Marchione, Mario Caccese, Giulia Midena, Vittorina Zagonel, Luisa Frizziero
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
This study aimed to prospectively evaluate, on a long-term basis, corneal side effects secondary to compassionate administration of epidermal growth factor receptor (EGFR) inhibitor depatuxizumab mafodotin (ABT-414) in patients affected by EGFR-ampli
Externí odkaz:
https://doaj.org/article/d3d19b8847034401920262f345d146a2
Publikováno v:
Biochemistry and Biophysics Reports, Vol 22, Iss , Pp - (2020)
Current antiviral therapy can not cure chronic hepatitis B virus (HBV) infection or eliminate the risk of hepatocellular carcinoma. The licensed epidermal growth factor receptor (EGFR) inhibitors have found to inhibit hepatitis C virus replication vi
Externí odkaz:
https://doaj.org/article/a953b4179e2246d2b128896ec8705f5b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Cancer Management and Research, Vol Volume 9, Pp 225-228 (2017)
Kara Capriotti,1,2 Joseph Capriotti,1,3 Jesse Pelletier,1,3 Kevin Stewart1,3 1Veloce BioPharma LLC, Fort Lauderdale, FL, 2Bryn Mawr Skin and Cancer Institute, Rosemont, PA, 3Plessen Ophthalmology Consultants, Christiansted, VI, USA Background: Nail c
Externí odkaz:
https://doaj.org/article/482bc85056c548c588cd5e3ce44d0750